Hepatitis B e antigen negative

2 trials MedDRA PT
2 Registered trials
0 Recruiting
2 Unique sponsors
5 Unique IMPs
0 Commercial trials
Drug classes (ATC)
J Anti-infectives (ATC J) 3
Mechanism of action (INN-stem analysis)
Antiviral 3 substances
Unknown / small molecule 2 substances
Phase II: 3

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase II

3 trials
  • ANRS Maladies Infectieuses Emergentes Academic
    ENTECAVIR; SELGANTOLIMOD; TENOFOVIR ALAFENAMIDE; TENOFOVIR DISOPROXIL
    2024-515739-32-00 4 countries 2022 n=51
    Ended
  • Medizinische Hochschule Hannover Academic
    HUMAN HEPATITIS B IMMUNOGLOBULIN
    2024-513792-41-00 1 country 2022 n=20
    Ended
  • Medizinische Hochschule Hannover Academic
    HUMAN HEPATITIS B IMMUNOGLOBULIN
    2024-513792-41-00 1 country 2022 n=20
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Medizinische Hochschule Hannover Academic 2 Phase II 0
ANRS Maladies Infectieuses Emergentes Academic 1 Phase II 0
New trials by year
2022
3
← All indication landscapes